Oxaliplatin is a diaminocyclohexane (DACH) platin.

• Number 5 product of Sanofi-Aventis
• Indications: early and advanced stages of colorectal cancer
• Licensees: Sanofi-Aventis (Eloxatin®), Yakult (Elplat®), Dr Reddy’s Laboratories (Dacotin®), Pfizer (Dacplat®)
• Current licensee sales of $2.2 B

Eloxatin® History

Licensed-in
In 1989, from Nagoya University

Status at in-licensing
Clinical phase I

• Developing oxaliplatin and working in particular on its efficacy-safety ratio
• File submission in France (Reference Member State)
• 15 patent families covering process, combination, formulation and use
• Continuous life cycle management

• First approval obtained in Europe in 1996 within seven years of in-licensing
• Record 46-day Food and Drug Administration (FDA) approval in 2002 in the United States
• Launch of the aqueous formulation in 2006

Selected Publications